Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 1109 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

AstraZeneca, PTC ink research, licensing pact

As per the terms of the agreement, PTC is eligible to receive an undisclosed up-front payment and research funding from AstraZenecafor executing first target under the pact. Additionally,

PharmStar Pharma expands Aquaprin product line

AQUAPRIN CHILDREN & TEENAGERS contains 81mg of aspirin and delivers approximately 65 mg of heart-healthy potassium. Like regular Aquaprin, the product is designed to dissolve on contact with

Progenics files Relistor sNDA with FDA

Relistor is indicated as a treatment for opioid-induced constipation (OIC) in patients with chronic, non-cancer pain. The drug is currently approved in the US, Australia, European Union, Canada